LU91672I2 - ChondroCelect - Google Patents

ChondroCelect

Info

Publication number
LU91672I2
LU91672I2 LU91672C LU91672C LU91672I2 LU 91672 I2 LU91672 I2 LU 91672I2 LU 91672 C LU91672 C LU 91672C LU 91672 C LU91672 C LU 91672C LU 91672 I2 LU91672 I2 LU 91672I2
Authority
LU
Luxembourg
Prior art keywords
chondrocytes
outcome
stability
articular
suspension
Prior art date
Application number
LU91672C
Other languages
English (en)
Original Assignee
Tigenix Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tigenix Nv filed Critical Tigenix Nv
Publication of LU91672I2 publication Critical patent/LU91672I2/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
    • A61K49/0006—Skin tests, e.g. intradermal testing, test strips, delayed hypersensitivity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
    • A61K49/0008—Screening agents using (non-human) animal models or transgenic animal models or chimeric hosts, e.g. Alzheimer disease animal model, transgenic model for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/975—Kit

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pathology (AREA)
  • Rheumatology (AREA)
  • Toxicology (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Zoology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Materials For Medical Uses (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
LU91672C 1999-10-06 2010-04-02 ChondroCelect LU91672I2 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP99203273 1999-10-06
EP00967443A EP1218037B1 (fr) 1999-10-06 2000-10-06 Analyse in vivo permettant de tester la stabilite phenotypique
PCT/BE2000/000118 WO2001024833A2 (fr) 1999-10-06 2000-10-06 Analyse in vivo et marqueurs moleculaires permettant de tester la stabilite phenotypique de populations de cellules et de selectionner des populations de cellules destinees a une transplantation autologue

Publications (1)

Publication Number Publication Date
LU91672I2 true LU91672I2 (fr) 2010-06-02

Family

ID=8240723

Family Applications (1)

Application Number Title Priority Date Filing Date
LU91672C LU91672I2 (fr) 1999-10-06 2010-04-02 ChondroCelect

Country Status (12)

Country Link
US (2) US7479367B1 (fr)
EP (2) EP1498146A3 (fr)
AT (1) ATE285797T1 (fr)
AU (1) AU7764200A (fr)
CA (1) CA2397610C (fr)
CY (1) CY2010007I2 (fr)
DE (3) DE60017159T2 (fr)
DK (1) DK1218037T3 (fr)
ES (2) ES2234673T3 (fr)
LU (1) LU91672I2 (fr)
PT (1) PT1218037E (fr)
WO (1) WO2001024833A2 (fr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7482114B2 (en) 1999-10-06 2009-01-27 Tigenix N.V. In vivo assay and molecular markers for testing the phenotypic stability of cell populations, and selected cell populations for autologous transplantation
ATE285797T1 (de) * 1999-10-06 2005-01-15 Tigenix Nv In vivo assay zur prüfung der phänotypischen stabilität
AU2001266915A1 (en) * 2000-06-14 2001-12-24 Case Western Reserve University Probes for chondrogenesis
US7462448B2 (en) * 2002-08-02 2008-12-09 Stratatech Corporation Species specific DNA detection
CA2646488A1 (fr) 2006-03-20 2007-09-27 Tigenix N.V. Methodes permettant de preserver, ameliorer et restaurer le phenotype cartilagineux des chondrocytes
EP2094310B1 (fr) 2006-11-24 2013-12-25 Tigenix N.V. Gènes marqueurs servant à identifier la stabilité de chondrocytes phenotypiques et au criblage de facteurs influencant la production de cartilage
CN101215565B (zh) * 2008-01-11 2011-04-27 华中农业大学 一种作为猪标记辅助选择的与免疫性状相关的分子标记的克隆及应用
GB0902793D0 (en) 2009-02-20 2009-04-08 Univ Gent GDF15 as molecular tool to monitor and enhance phenotypic stability of articular chondrocytes
EP3872168A1 (fr) * 2020-02-28 2021-09-01 Cline Scientific AB Différenciation de chondrocytes
MX2023002106A (es) 2020-08-21 2023-03-15 Genzyme Corp Anticuerpos fgfr3 y metodos de uso.

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5837258A (en) * 1991-08-30 1998-11-17 University Of South Florida Induction of tissue, bone or cartilage formation using connective tissue growth factor
US5723331A (en) 1994-05-05 1998-03-03 Genzyme Corporation Methods and compositions for the repair of articular cartilage defects in mammals
US5902785A (en) * 1995-06-06 1999-05-11 Genetics Institute, Inc. Cartilage induction by bone morphogenetic proteins
DK0836380T3 (da) 1995-06-12 2002-04-22 Yeda Res & Dev FGF9 som en specifik ligand for FGFR3
WO1998053103A1 (fr) 1997-05-21 1998-11-26 Clontech Laboratories, Inc. Ensembles d'acide nucleique
AU7984498A (en) * 1997-06-25 1999-01-04 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Serum-free cell growth medium
US7482114B2 (en) 1999-10-06 2009-01-27 Tigenix N.V. In vivo assay and molecular markers for testing the phenotypic stability of cell populations, and selected cell populations for autologous transplantation
ATE285797T1 (de) * 1999-10-06 2005-01-15 Tigenix Nv In vivo assay zur prüfung der phänotypischen stabilität
CA2386506C (fr) * 1999-10-06 2012-02-21 Tigenix N.V. Isolement de cellules precurseurs et leur utilisation dans la reparation de tissus

Also Published As

Publication number Publication date
CA2397610A1 (fr) 2001-04-12
DE122010000021I1 (de) 2012-09-06
CY2010007I1 (el) 2010-07-28
CA2397610C (fr) 2012-07-03
DE60017159T2 (de) 2006-05-04
WO2001024833A2 (fr) 2001-04-12
ES2234673T3 (es) 2005-07-01
US7479367B1 (en) 2009-01-20
PT1218037E (pt) 2005-05-31
WO2001024833A3 (fr) 2001-12-20
ATE285797T1 (de) 2005-01-15
DE20023659U1 (de) 2005-07-07
CY2010007I2 (el) 2010-07-28
US20090162328A1 (en) 2009-06-25
EP1498146A3 (fr) 2007-01-24
DE60017159D1 (de) 2005-02-03
EP1498146A2 (fr) 2005-01-19
DK1218037T3 (da) 2005-04-25
US9089598B2 (en) 2015-07-28
AU7764200A (en) 2001-05-10
EP1218037A2 (fr) 2002-07-03
ES2488240T1 (es) 2014-08-26
EP1218037B1 (fr) 2004-12-29

Similar Documents

Publication Publication Date Title
LU91672I2 (fr) ChondroCelect
DE69927512D1 (de) Verwendung von op-1 zur herstellung einer pharmazeutischen zusammensetzung zur reparatur von nicht-gelenksknorpeldefekten eines säugers
SE9303977D0 (sv) Verfahren zur herstellung von implantatkeramikmaterial, insbesonders von hydroxylapatit aufweisenden implantatkeramikmaterial
DE69331319D1 (de) Biotin-DOTA Konjugate und deren Verwendung in "Pretargeting" Verfahren
ATE213590T1 (de) Fgf9 als spezifischer ligand für fgfr3
ATE330000T1 (de) Verwendung von fettgewebe-abgeleiteten stromalen zellen zur differenzierung in chondrozyten und ihre verwendung zur reparatur von knorpelgewebe
YU12201A (sh) Metodi, instrumenti i materijali za transplantaciju ćelija hondrocita
ATE143268T1 (de) Maytansinoid enthaltende cytotoxische mittel und ihre therapeutische anwendung
CY1109742T1 (el) Μεθοδοι και συνθεσεις για επουλωση και αποκατασταση αρθρικου χονδρου
ATE162403T1 (de) Modifizierte antikörper mit kontrollierter clearance-zeit
PT871476E (pt) Composicao seca de factor sanguineo compreendendo trealose
DE60113570D1 (de) Spritzgusspolymer
HK1161115A1 (en) Pharmaceutical compositions and methods useful for modulating angiogenesis
DK1130394T3 (da) In vitro-modeller af CNS-funktion og -dysfunktion
DK0795605T3 (da) Denatureret lavdensitetslipoprotein-receptor
DE69906745D1 (de) Quellbares saugfähiges produkt und verfahren zu seiner herstellung
DE60034672D1 (de) Reporterverbindungen und verfahren zur bestimmung des lipidisierungsstatus einer zelle
ES2151895T3 (es) Procedimiento para la obtencion de cultivos celulares con alto contenido en citoquinas endogenas.
DE69008466D1 (de) Verwendung des 6-[[3-[4-(2-Methoxyphenyl)-1-piperazinyl]propyl]amino]-1,3-Dimethyluracils zur Herstellung einer pharmazeutischen Zusammensetzung zur Behandlung von Harnwegsverstopfungen.
ATE455565T1 (de) Verwendung eines biologischen materials mit dreidimensionalen gerüsten aus hyaluronsäure- derivaten
DE59507162D1 (de) Verfahren zur Befestigung von Hängen
ATE192213T1 (de) Verfahren und grabvorrichtung zur herstellung von tunnelsohlen
ATE85893T1 (de) Verwendung von somatostatin zur herstellung eines arzneimittels fuer die behandlung von rheumatoider arthritis.
ATE238261T1 (de) Verfahren zur herstellung von orthoestern
ATE248218T1 (de) Humane hypertrophe chrondrozyten zelllinien